Novo Nordisk A/S - Share Repurchase Programme

(MENAFN- GlobeNewsWire - Nasdaq) Bagsværd, Denmark, 2 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 23 February 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	2,750,000		841,997,435
23 February 2026	275,000	267.50	73,563,182
24 February 2026	250,000	244.52	61,130,747
25 February 2026	250,000	240.03	60,006,450
26 February 2026	260,000	239.10	62,165,344
27 February 2026	260,000	237.81	61,830,481
Accumulated under the programme	4,045,000		1,160,693,639

The details for each transaction made under the share repurchase programme are published on novonordisk.

With the transactions stated above, Novo Nordisk owns a total of 21,434,799 B shares of DKK 0.10 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 27 February 2026, Novo Nordisk has since 4 February 2026 repurchased a total 4,045,000 B shares at an average share price of DKK 286.95 per B share equal to a transaction value of DKK 1,160,693,639.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 ...	Liz Skrbkova (US) +1 609 917 0632 ...
Investors:
Michael Novod +45 3075 6050 ...	Jacob Martin Wiborg Rode +45 3075 5956 ...
Max Ung +45 3077 6414 ...	Sina Meyer +45 3079 6656 ...
Alex Bruce +45 3444 2613 ...	Christoffer Sho Togo Tullin +45 3079 1471 ...
Frederik Taylor Pitter +1 609 613 0568 ...

Company Announcement No 15/2026

Attachments

• CA260302 safe harbour
• CA260302 safe harbour transaction details

MENAFN02032026004107003653ID1110808575